{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T11:54:06Z","timestamp":1792929246580,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.esmoop.2025.105079","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:51:35Z","timestamp":1746060695000},"page":"105079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Precision oncology in biliary tract cancer: the emerging role of liquid biopsy"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1219-029X","authenticated-orcid":false,"given":"M.","family":"de Scordilli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1364-5478","authenticated-orcid":false,"given":"M.","family":"Bortolot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2490-0556","authenticated-orcid":false,"given":"S.","family":"Torresan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Noto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-1201","authenticated-orcid":false,"given":"P.","family":"Di Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3571-2461","authenticated-orcid":false,"given":"A.","family":"Fumagalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-3502","authenticated-orcid":false,"given":"M.","family":"Guardascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-7092","authenticated-orcid":false,"given":"E.","family":"Ongaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Foltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4938","authenticated-orcid":false,"given":"F.","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.esmoop.2025.105079_bib1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.gastha.2022.04.007","article-title":"Worldwide incidence and mortality of biliary tract cancer","volume":"1","author":"Baria","year":"2022","journal-title":"Gastro Hep Adv"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105079_bib2","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"issue":"15","key":"10.1016\/j.esmoop.2025.105079_bib3","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/j.ejca.2015.07.034","article-title":"Survival in patients with primary liver cancer, gallbladder and extrahepatic biliary tract cancer and pancreatic cancer in Europe 1999\u20132007: results of EUROCARE-5","volume":"51","author":"Lepage","year":"2015","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105079_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105079_bib5","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.3390\/cancers14174277","article-title":"Liquid biopsy, an everchanging balance between clinical utility and emerging technologies","volume":"14","author":"Cucciniello","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.esmoop.2025.105079_bib6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1200\/PO.20.00345","article-title":"Longitudinal dynamics of circulating tumor cells and circulating tumor DNA for treatment monitoring in metastatic breast cancer","volume":"5","author":"Gerratana","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmoop.2025.105079_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104242","article-title":"Liquid biopsy in colorectal cancer: onward and upward","volume":"194","author":"Torresan","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105079_bib8","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2023.11.030","article-title":"Battle of the biopsies: role of tissue and liquid biopsy in hepatocellular carcinoma","volume":"80","author":"Lehrich","year":"2024","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105079_bib9","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.biotechadv.2013.08.016","article-title":"Detection and isolation of circulating tumor cells: principles and methods","volume":"31","author":"Esmaeilsabzali","year":"2013","journal-title":"Biotechnol Adv"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hep.27944","article-title":"Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma","volume":"63","author":"Yang","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.esmoop.2025.105079_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.941660","article-title":"Circulating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma","volume":"12","author":"Fr\u00fcndt","year":"2022","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105079_bib12","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1002\/ijc.32822","article-title":"A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer","volume":"146","author":"Reduzzi","year":"2020","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105079_bib13","doi-asserted-by":"crossref","first-page":"173","DOI":"10.21873\/cgp.20029","article-title":"Next-generation sequencing (NGS) analysis on single circulating tumor cells (CTCs) with no need of whole-genome amplification (WGA)","volume":"14","author":"Palmirotta","year":"2017","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib14","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3390\/cancers14010233","article-title":"Circulating cell-free DNA-based comprehensive molecular analysis of biliary tract cancers using next-generation sequencing","volume":"14","author":"Csoma","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105079_bib15","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1158\/2159-8290.CD-15-0274","article-title":"Cell-free DNA next-generation sequencing in pancreatobiliary carcinomas","volume":"5","author":"Zill","year":"2015","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105079_bib16","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/diagnostics11060999","article-title":"Diagnostic and prognostic value of circulating cell-free DNA for cholangiocarcinoma","volume":"11","author":"Wintachai","year":"2021","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105079_bib17","doi-asserted-by":"crossref","first-page":"S1041","DOI":"10.1016\/S0016-5085(17)33526-6","article-title":"Detection of cholangiocarcinoma by assay of methylated DNA markers in plasma","volume":"152","author":"Yang","year":"2017","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-016-0299-x","article-title":"Promoter hypermethylation of SHOX2 and SEPT9 is a potential biomarker for minimally invasive diagnosis in adenocarcinomas of the biliary tract","volume":"8","author":"Branchi","year":"2016","journal-title":"Clin Epigenetics"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13148-019-0634-0","article-title":"Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases","volume":"11","author":"Wasenang","year":"2019","journal-title":"Clin Epigenetics"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib20","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12916-021-02197-w","article-title":"Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes","volume":"20","author":"Qiu","year":"2022","journal-title":"BMC Med"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105079_bib21","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105079_bib22","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion\u2013positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib23","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci Rep"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2025.105079_bib24","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1200\/JCO.2020.38.15_suppl.4576","article-title":"IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study","volume":"38","author":"Aguado","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105079_bib25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.tips.2019.01.006","article-title":"Liquid biopsies in cancer diagnosis, monitoring, and prognosis","volume":"40","author":"De","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105079_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14737159.2018.1425143","article-title":"The potential of circulating cell-free RNA as a cancer biomarker: challenges and opportunities","volume":"18","author":"Zaporozhchenko","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105079_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11523-020-00717-x","article-title":"MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as new tools for cancer therapy: first steps from bench to bedside","volume":"15","author":"Ratti","year":"2020","journal-title":"Target Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105079_bib28","first-page":"3870","article-title":"Exosomal miR-200 family as serum biomarkers for early detection and prognostic prediction of cholangiocarcinoma","volume":"12","author":"Shen","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105079_bib29","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.2217\/pgs-2017-0010","article-title":"miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma","volume":"18","author":"Puik","year":"2017","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.esmoop.2025.105079_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jconrel.2022.08.010","article-title":"Multi-omics analysis revealed the role of extracellular vesicles in hepatobiliary & pancreatic tumor","volume":"350","author":"Gongye","year":"2022","journal-title":"J Control Release"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2023.02.027","article-title":"Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma","volume":"79","author":"Lapitz","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105079_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jhep.2017.02.024","article-title":"Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma","volume":"67","author":"Julich-Haertel","year":"2017","journal-title":"J Hepatol"},{"issue":"18","key":"10.1016\/j.esmoop.2025.105079_bib33","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3390\/cancers13184581","article-title":"Liquid biopsy from bile-circulating tumor DNA in patients with biliary tract cancer","volume":"13","author":"Han","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105079_bib34","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1080\/15384047.2018.1456604","article-title":"Liquid biopsy of bile for the molecular diagnosis of gallbladder cancer","volume":"19","author":"Kinugasa","year":"2018","journal-title":"Cancer Biol Ther"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105079_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139305","article-title":"MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and\/or cholangiocarcinoma","volume":"10","author":"Voigtl\u00e4nder","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2025.105079_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HEP.0000000000000437","article-title":"Bile exosomal miR-182\/183-5p increases cholangiocarcinoma stemness and progression by targeting HPGD and increasing PGE2 generation","volume":"79","author":"Shu","year":"2024","journal-title":"Hepatology"},{"issue":"41","key":"10.1016\/j.esmoop.2025.105079_bib37","doi-asserted-by":"crossref","first-page":"69995","DOI":"10.18632\/oncotarget.19547","article-title":"The diagnostic\/prognostic potential and molecular functions of long non-coding RNAs in the exosomes derived from the bile of human cholangiocarcinoma","volume":"8","author":"Ge","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105079_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100275","article-title":"Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer","volume":"6","author":"Gou","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib39","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/hep.32125","article-title":"Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile","volume":"75","author":"Vedeld","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.esmoop.2025.105079_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2023.117593","article-title":"Bile liquid biopsy in biliary tract cancer","volume":"551","author":"Liu","year":"2023","journal-title":"Clinica Chimica Acta"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib41","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12253-016-0087-0","article-title":"Quantification of circulating free DNA as a diagnostic marker in gall bladder cancer","volume":"23","author":"Kumari","year":"2017","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-018-1677-2","article-title":"Fragment size and level of cell-free DNA provide prognostic information in patients with advanced pancreatic cancer","volume":"16","author":"Lapin","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.esmoop.2025.105079_bib43","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijid.2017.12.002","article-title":"Diagnostic value of circulating cell-free DNA levels for hepatocellular carcinoma","volume":"67","author":"Yan","year":"2018","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1055\/s-0038-1676097","article-title":"Noncoding RNA in cholangiocarcinoma","volume":"39","author":"Salati","year":"2019","journal-title":"Semin Liver Dis"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105079_bib45","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/cas.12300","article-title":"Plasma miR-21 is a novel diagnostic biomarker for biliary tract cancer","volume":"104","author":"Kishimoto","year":"2013","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib46","doi-asserted-by":"crossref","DOI":"10.1038\/srep16103","article-title":"Circulating miR-106a is a novel prognostic and lymph node metastasis indicator for cholangiocarcinoma","volume":"5","author":"Cheng","year":"2015","journal-title":"Sci Rep"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105079_bib47","doi-asserted-by":"crossref","first-page":"18631","DOI":"10.18632\/oncotarget.4072","article-title":"Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105079_bib48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jhep.2014.10.004","article-title":"miR-122\u2014a key factor and therapeutic target in liver disease","volume":"62","author":"Bandiera","year":"2015","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/cei.12776","article-title":"Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma","volume":"185","author":"Bernuzzi","year":"2016","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105079_bib50","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3892\/or.2014.3641","article-title":"Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol Rep"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105079_bib51","doi-asserted-by":"crossref","first-page":"15019","DOI":"10.1007\/s13277-016-5313-6","article-title":"Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma","volume":"37","author":"Wu","year":"2016","journal-title":"Tumor Biol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105079_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118220","article-title":"MicroRNA markers for the diagnosis of pancreatic and biliary-tract cancers","volume":"10","author":"Kojima","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105079_bib53","first-page":"97","article-title":"Detection of circulating tumor cells in cancers of biliary origin","volume":"3","author":"Ustwani","year":"2012","journal-title":"J Gastrointest Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105079_bib54","first-page":"3429","article-title":"EpCAM-based flow cytometric detection of circulating tumor cells in gallbladder carcinoma cases","volume":"18","author":"Awasthi","year":"2017","journal-title":"Asian Pac J Cancer Prev"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105079_bib55","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.3390\/jcm10194435","article-title":"Vimentin-positive circulating tumor cells as diagnostic and prognostic biomarkers in patients with biliary tract cancer","volume":"10","author":"Han","year":"2021","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105079_bib56","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/cells9030721","article-title":"Patients with cholangiocarcinoma present specific RNA profiles in serum and urine extracellular vesicles mirroring the tumor expression: novel liquid biopsy biomarkers for disease diagnosis","volume":"9","author":"Lapitz","year":"2020","journal-title":"Cells"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2025.105079_bib57","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.2021.39.3_suppl.336","article-title":"Role of ctDNA to predict risk of recurrence following potentially curative resection of biliary tract and pancreatic malignancies","volume":"39","author":"Lamarca","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105079_bib58","article-title":"Detecting early recurrence with circulating tumor DNA in stage I-III biliary tract cancer after curative resection","volume":"9","author":"Yu","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"14","key":"10.1016\/j.esmoop.2025.105079_bib59","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105079_bib60","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"J Clin Oncology"},{"issue":"10391","key":"10.1016\/j.esmoop.2025.105079_bib61","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105079_bib62","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105079_bib63","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-21-2384","article-title":"ESMO Scale for Clinical Actionability of Molecular Targets driving targeted treatment in patients with cholangiocarcinoma","volume":"28","author":"Verdaguer","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105079_bib64","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105079_bib65","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105079_bib66","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.esmoop.2025.105079_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104224","article-title":"Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts\u2019 position paper","volume":"194","author":"Fassan","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.esmoop.2025.105079_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102649","article-title":"Molecular profiling in cholangiocarcinoma: a practical guide to next-generation sequencing","volume":"122","author":"Stenzinger","year":"2024","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105079_bib69","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2025.105079_bib70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2019.37.4_suppl.291","article-title":"Landscape of circulating tumor DNA and tissue-based profiling in advanced cholangiocarcinoma","volume":"37","author":"Mody","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105079_bib71","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","article-title":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","volume":"82","author":"Hwang","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.esmoop.2025.105079_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00324","article-title":"Circulating tumor DNA profiling of advanced biliary tract cancers","volume":"3","author":"Mody","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"19","key":"10.1016\/j.esmoop.2025.105079_bib73","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-23-3780","article-title":"Clinical value of liquid biopsy in patients with FGFR2 fusion\u2013positive cholangiocarcinoma during targeted therapy","volume":"30","author":"Gonz\u00e1lez-Medina","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105079_bib74","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/ijc.33230","article-title":"Comprehensive genomic landscape and precision therapeutic approach in biliary tract cancers","volume":"148","author":"Okamura","year":"2021","journal-title":"Int J Cancer"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105079_bib75","article-title":"Liquid biopsy-based prediction of clinical benefit from immune checkpoint inhibitors in advanced biliary tract cancer","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105079_bib76","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1158\/2159-8290.CD-20-0766","article-title":"Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib","volume":"11","author":"Silverman","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2025.105079_bib77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/PO.20.00178","article-title":"Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","volume":"5","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105079_bib78","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib79","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"21","key":"10.1016\/j.esmoop.2025.105079_bib80","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/1078-0432.CCR-24-1834","article-title":"Understanding and overcoming resistance to selective FGFR inhibitors across FGFR2-driven malignancies","volume":"30","author":"Facchinetti","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105079_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102627","article-title":"Resistance mechanism to fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma","volume":"121","author":"Lamarca","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2025.105079_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/S0959-8049(22)01110-8","article-title":"Identifying FGFR2 fusions\/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor","volume":"174","author":"Schram","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2025.105079_bib83","article-title":"Monitoring of dynamic changes and clonal evolution in circulating tumor DNA from patients with IDH-mutated cholangiocarcinoma treated with isocitrate dehydrogenase inhibitors","volume":"6","author":"Lapin","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105079_bib84","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105079_bib85","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.esmoop.2025.105079_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108170","article-title":"Ivosidenib in IDH1-mutated cholangiocarcinoma: clinical evaluation and future directions","volume":"237","author":"Lavacchi","year":"2022","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105079_bib87","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1200\/JCO.23.01193","article-title":"Trastuzumab plus gemcitabine-cisplatin for treatment-na\u00efve human epidermal growth factor receptor 2\u2013positive biliary tract adenocarcinoma: a multicenter, open-label, phase II study (TAB)","volume":"42","author":"Ostwal","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105079_bib88","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.31094","article-title":"Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells","volume":"72","author":"Carotenuto","year":"2020","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105079_bib89","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1053\/j.gastro.2006.02.057","article-title":"Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines","volume":"130","author":"Meng","year":"2006","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105079_bib90","doi-asserted-by":"crossref","first-page":"3092","DOI":"10.1038\/bjc.2013.655","article-title":"Direct targeting of SUZ12\/ROCK2 by miR-200b\/c inhibits cholangiocarcinoma tumourigenesis and metastasis","volume":"109","author":"Peng","year":"2013","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105079_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077623","article-title":"miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells","volume":"8","author":"Okamoto","year":"2013","journal-title":"PLoS One"},{"issue":"32","key":"10.1016\/j.esmoop.2025.105079_bib92","doi-asserted-by":"crossref","first-page":"52913","DOI":"10.18632\/oncotarget.17577","article-title":"miR-106b regulates the 5-fluorouracil resistance by targeting Zbtb7a in cholangiocarcinoma","volume":"8","author":"Jiao","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105079_bib93","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1245\/s10434-017-5871-x","article-title":"Micro-RNA-130a-3p regulates gemcitabine resistance via PPARG in cholangiocarcinoma","volume":"24","author":"Asukai","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2025.105079_bib94","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.2024.42.3_suppl.528","article-title":"The role of pre-operative ctDNA in resectable intrahepatic cholangiocarcinoma","volume":"42","author":"Choi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105079_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.1609879","article-title":"Genomic profiling of blood-derived circulating tumor DNA from patients with advanced biliary tract cancer","volume":"27","author":"Chen","year":"2021","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.esmoop.2025.105079_bib96","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.3390\/jcm9092854","article-title":"Molecular profiling in daily clinical practice: practicalities in advanced cholangiocarcinoma and other biliary tract cancers","volume":"9","author":"Lamarca","year":"2020","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105079_bib97","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/onco.13844","article-title":"Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns","volume":"26","author":"Israel","year":"2021","journal-title":"Oncologist"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925009482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:44:22Z","timestamp":1762598662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925009482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2059702925009482"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105079","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision oncology in biliary tract cancer: the emerging role of liquid biopsy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105079"}}